What is it about?
We describe what we have learned from four years of collaborating across the industry/not-for-profit boundary. Over this time we pursued multiple projects and some of the lessons learned are described here.
Featured Image
Why is it important?
Many large pharma companies have reduced their research activity at the very early, hit- and lead- seeking phase of research. To compensate, organisations are becoming more porous and working more collaboratively in risk-sharing arrangements. Both parties need to give up some control, but gain a great deal in return.
Read the Original
This page is a summary of: Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface, Drug Discovery Today, April 2014, Elsevier,
DOI: 10.1016/j.drudis.2014.01.009.
You can read the full text:
Resources
Contributors
The following have contributed to this page
